Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A
Prophylactic treatment with rAHF-PFM is likely more cost effective than BAY 81-8973 for Chinese PUPs with severe hemophilia A. This finding is primarily driven by the lower incidence of inhibitor development and fewer bleeding episodes associated with rAHF-PFM in the model.
Authors
- Genyong Zuo (ORCID: https://orcid.org/0000-0002-9305-9671)
- Congling Gu
- Zhenguo Wang (ORCID: https://orcid.org/0000-0002-8932-4532)
- Jie Peng (ORCID: https://orcid.org/0000-0002-6914-8260)
- Yang Li (ORCID: https://orcid.org/0000-0002-5850-3191)
Institutions
- Central South University (CN)
- Shandong University (CN)
- University of Jinan (CN)
- Jinan Maternity And Care Hospital (CN)
- Xiangya Hospital Central South University (CN)
- Chinese Academy of International Trade and Economic Cooperation (CN)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1007/s41669-025-00623-w
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00